FTC Inquiry into Pharmacy Benefit Managers and Drug Pricing

When you pick up a prescription, the price on your card reflects a chain of middlemen: drug manufacturer, wholesaler, pharmacy, insurer, and often a pharmacy benefit manager. PBMs create formularies—the lists that say which drugs are covered and at what copay tier.

Three PBMs handle a large share of US prescriptions. Several are owned by or tied to major insurers and retail pharmacy chains. That vertical stack means the same corporate family may negotiate drug prices, run the mail-order pharmacy, and set reimbursement for competing drugstores.

Independent pharmacists have complained for years that PBM 'take-it-or-leave-it' contracts include clawbacks, low reimbursement, and steering to affiliated mail-order or specialty pharmacies. Patients have complained about surprise costs, especially for insulin and specialty drugs.

In June 2022 the FTC launched a formal inquiry using compulsory orders—a rare deep dive. The agency sought data on rebates, spread pricing, fees charged to pharmacies, and practices that might exclude smaller competitors.

PBMs respond that they save payers billions through negotiation, that rebates lower premiums, and that formulary design encourages use of safe, effective, lower-cost medicines. They caution against blaming middlemen for complex drug pricing rooted in patent exclusivity and manufacturer list prices.

In February 2026 the FTC settled with Express Scripts. In July 2026 it settled with Caremark. Both deals change rebate and pharmacy terms. They are not a trial verdict.

OptumRx was the remaining respondent. The case was pulled from adjudication so the Commission could consider a proposed consent. Until that consent is approved, the docket stays open.

PBM rules can determine whether your local pharmacy survives and whether you pay cash price or copay at the counter.

Insulin and specialty drug affordability debates often lead back to formulary design and rebate mechanics few patients see.

Vertical integration in health care mirrors tech platform conflicts—middlemen who also compete with their customers.

FTC attention may change disclosure rules even before any lawsuit succeeds.

PBMs possess market power in negotiating drug benefits for major payers.

Opaque rebate and fee structures may inflate list prices and harm independent pharmacies.

Vertical ties to insurers and pharmacies create incentives to self-preference affiliated services.

Formulary and reimbursement rules may restrict patient choice and raise out-of-pocket costs.

PBMs say they deliver savings through bulk negotiation and generic encouragement.

They argue manufacturers set list prices and patent strategies drive high costs more than PBM fees.

They maintain pharmacies remain free to contract and patients can appeal coverage decisions.

Industry groups warn structural remedies could reduce plan flexibility.

Ask your pharmacist if a PBM fee or 'DIR clawback' affects your price—many patients never hear those terms until bills spike.

Employers and unions can demand PBM transparency in plan renewals even while the FTC probe continues.

Watch state bills on PBM licensing and spread pricing; federal and state efforts may overlap.

Until cases conclude, no assumption that all PBM practices are illegal—only that regulators are actively scrutinizing them.